Risk-based screening turns a blind eye to many breast cancers in 40-something women

Screening mammography of women in their 40s based solely on risk as flagged by extremely dense breasts, very strong family history or both would lead to much higher mortality on the heels of more than 75 percent fewer screen-detected cancers in this group.

That’s from a study running in the December edition of the American Journal of Roentgenology.

Elissa Price, MD, of UC-San Francisco and colleagues retrospectively identified all cancers detected by screening mammography in women 40 to 49 years old at UCSF Medical Center between January 1997 and November 2012.

After excluding women with a personal history of breast cancer, they noted family history, breast density, type of malignancy, hormone receptor status and lymph node status.

From a field of 39,715 screening exams, the researchers recorded 136 cancers (cancer detection rate, 3.4 per 1,000).

Most tellingly, some 104 of the 136 patients—76 percent—had neither very strong family history nor extremely dense breasts.

Meanwhile, very strong family history was absent in the vast majority (119 of 136, or 87.5 percent), and extremely dense breast tissue was absent in like proportion (117 of 136, or 86 percent).

Among all three groups of low-risk patients, 79 percent had invasive cancers, of which 25 percent had axillary nodal involvement and 89 percent were estrogen receptor-positive.

Even looking at a risk-based strategy with an expanded definition of high risk—any first-degree family history or extremely dense tissue—the team found that 66 percent of malignancies would still be missed.

In their study discussion, Price et al. state that using very strong family history and/or extremely dense tissue as a foundation for risk-based screening strategies “would have failed to capture the great majority of cancers in our young population. These are women who develop consequential cancer that is often invasive and node-positive, but that is also likely to be treated successfully." 

The study was first presented at RSNA 2014. 

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.